Medication-Assisted Treatment (MAT) in Inpatient Opiate Rehab

Medication-assisted treatment combines FDA-approved medications with the counseling, therapy, and structure of inpatient opioid rehab. When the medications are integrated into a complete residential program, the combination is the most effective treatment available for opioid use disorder.

What Inpatient MAT Is

Medication-Assisted Treatment, or MAT, is the use of FDA-approved medications alongside counseling and behavioral therapy to treat opioid use disorder. The three medications approved for treating OUD are buprenorphine, methadone, and naltrexone. Inside an inpatient opiate rehab program, MAT is one component of a complete treatment plan — alongside individual therapy, group therapy, psychiatric care, and discharge planning. Inpatient MAT differs from outpatient MAT in that the medication is started, titrated, and stabilized within a structured 24-hour residential setting where the patient is medically supervised, removed from triggers, and receiving the full therapeutic programming of residential rehab simultaneously.

The Three Primary MAT Medications

Buprenorphine (Subutex, Suboxone, Sublocade, Brixadi)

Buprenorphine is a partial opioid agonist — it binds to the same receptors as heroin and prescription opioids but produces a much weaker effect, suppressing withdrawal and cravings without producing significant euphoria at therapeutic doses. It is the most commonly used MAT medication for opioid use disorder in the United States. Inside an inpatient program, buprenorphine is typically:

• Started during the detox phase (induction) once the patient is in objective withdrawal
• Titrated up over 24–48 hours to a stable maintenance dose, usually 8–16 mg/day
• Continued throughout the residential stay as part of MAT
• Continued post-discharge through a community provider, sometimes as a monthly injection (Sublocade or Brixadi)

The combination form, buprenorphine-naloxone (brand name Suboxone), includes naloxone as a deterrent to misuse — if the medication is injected rather than taken sublingually, the naloxone precipitates withdrawal. For patients who take Suboxone correctly, the naloxone has no clinical effect.

Methadone

Methadone is a full opioid agonist used for opioid use disorder in federally licensed opioid treatment programs. Inside an inpatient setting, methadone may be used during detox to manage severe withdrawal — particularly for patients with very high opioid tolerance or for those who do not respond well to buprenorphine. Long-term methadone maintenance is restricted to federally licensed opioid treatment programs and is typically continued in the community after the inpatient stay rather than dispensed by the residential facility itself.

Extended-Release Naltrexone (Vivitrol)

Naltrexone is an opioid antagonist — it blocks opioid receptors so that any opioid taken has no effect. Vivitrol is the once-monthly extended-release injectable form. Because the patient must be fully opioid-free (typically 7–10 days) before the first injection, Vivitrol is often initiated near the end of the detox phase inside an inpatient program. After discharge, the patient receives a Vivitrol injection once per month from a community provider. Vivitrol is not itself an opioid, produces no euphoria, and creates no physical dependence — which makes it appealing to patients who want to be completely off opioids while still having pharmacological protection against relapse.

Why MAT Inside an Inpatient Program Is Different

Most discussion of MAT focuses on outpatient or community-based treatment. Inpatient MAT — meaning MAT initiated and stabilized within a residential opioid rehab program — has several clinical advantages:

• Medical supervision during induction. The first 48 hours of buprenorphine induction can be uncomfortable if the timing is off. In an inpatient setting, nurses and physicians manage the process around the clock, adjusting doses as needed.
• Removal from triggers. The patient is not at home, not around drug-using peers, and not navigating the stress of work and relationships during the most fragile early days. This dramatically improves induction success.
• Integration with therapy. The patient receives 30+ hours of clinical programming per week — individual therapy, group, education — at the same time the medication is being stabilized. The behavioral and pharmacological treatment reinforce each other.
• Stabilized dosing before discharge. The patient leaves with a stable maintenance dose, a community provider, and the first prescription or injection in hand — not just a referral.

Who Benefits Most from Inpatient MAT

• Patients with severe opioid use disorder, particularly involving heroin or fentanyl
• Patients with multiple prior treatment episodes or relapse history
• Patients with significant withdrawal symptoms that did not respond to outpatient management
• Patients with co-occurring mental health conditions that make outpatient adherence difficult
• Patients who lack a stable, sober home environment
• Patients who want to start long-term injectable buprenorphine or naltrexone but need a safe place to complete the prerequisite detox

What Inpatient MAT Does Not Replace

Medication is essential for many patients, but it is not the entire treatment. Patients who receive MAT alone — without the therapy, structure, family work, and discharge planning of inpatient rehab — have lower retention and higher relapse rates than patients who receive integrated care. The most effective inpatient programs treat MAT as one tool among several, not as a stand-in for behavioral and social recovery work.

Frequently Asked Questions

What is MAT in drug rehab?

Medication-Assisted Treatment (MAT) is the combination of FDA-approved medications with counseling and behavioral therapies to treat substance use disorders. For opioid use disorder, the three primary MAT medications are buprenorphine (and its combination form Suboxone), methadone, and extended-release naltrexone (Vivitrol). Inside an inpatient rehab program, MAT is one component of a complete clinical plan — it is not a replacement for therapy, structure, and aftercare.

Is MAT the same as rehab?

No. MAT is one of several evidence-based components of a complete inpatient opioid rehab program. The medication addresses the neurobiological side of opioid dependence — withdrawal, cravings, and the brain's adapted reward system — while individual therapy, group therapy, family programming, psychiatric care, and discharge planning address the behavioral, emotional, and social dimensions. MAT alone, without the rest, has lower success rates than MAT integrated into comprehensive residential treatment.

How long does MAT treatment last?

The duration of medication-assisted treatment is highly individualized and is determined by the patient and their treating clinician — not by the inpatient program length. Some patients use MAT only during the inpatient stay as part of detox. Others start MAT inside the inpatient program and continue on it for 6 months, 12 months, or indefinitely as part of long-term recovery. Research consistently shows that longer durations of MAT correlate with lower relapse rates and lower mortality from opioid use disorder.

Will I be dependent on Suboxone forever?

Buprenorphine (the active ingredient in Suboxone) is itself a long-acting opioid, and patients on it are physically dependent in the same sense that someone on insulin or blood pressure medication is physiologically dependent on those medications. The relevant question is not whether the patient is dependent on a medication — it's whether the medication is helping. Long-term buprenorphine maintenance dramatically reduces overdose mortality, illicit opioid use, and criminal activity. Many patients taper off after 1–2 years; others stay on indefinitely. Both are clinically appropriate.

What is Vivitrol and how does it work?

Vivitrol is the brand name for extended-release injectable naltrexone. It is a once-monthly injection of an opioid antagonist — a medication that blocks the opioid receptors in the brain so that opioids cannot produce their effect. Unlike buprenorphine, naltrexone is not itself an opioid and produces no euphoria, sedation, or physical dependence. The patient must be fully detoxed (typically 7–10 days opioid-free) before receiving the first injection, which is one reason Vivitrol is often started inside an inpatient program where detox is already complete.